Giant prolactinomas in women

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Giant prolactinomas in women. / Delgrange, Etienne; Raverot, Gerald; Bex, Marie; Burman, Pia; Decoudier, Benedicte; Devuyst, France; Feldt-Rasmussen, Ulla; Andersen, Marianne; Maiter, Dominique.

I: European Journal of Endocrinology, Vol. 170, Nr. 1, 2014, s. 31-38.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Delgrange, E, Raverot, G, Bex, M, Burman, P, Decoudier, B, Devuyst, F, Feldt-Rasmussen, U, Andersen, M & Maiter, D 2014, 'Giant prolactinomas in women', European Journal of Endocrinology, vol. 170, nr. 1, s. 31-38. https://doi.org/10.1530/EJE-13-0503

APA

Delgrange, E., Raverot, G., Bex, M., Burman, P., Decoudier, B., Devuyst, F., ... Maiter, D. (2014). Giant prolactinomas in women. European Journal of Endocrinology, 170(1), 31-38. https://doi.org/10.1530/EJE-13-0503

CBE

Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D. 2014. Giant prolactinomas in women. European Journal of Endocrinology. 170(1):31-38. https://doi.org/10.1530/EJE-13-0503

MLA

Vancouver

Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F et al. Giant prolactinomas in women. European Journal of Endocrinology. 2014;170(1):31-38. https://doi.org/10.1530/EJE-13-0503

Author

Delgrange, Etienne ; Raverot, Gerald ; Bex, Marie ; Burman, Pia ; Decoudier, Benedicte ; Devuyst, France ; Feldt-Rasmussen, Ulla ; Andersen, Marianne ; Maiter, Dominique. / Giant prolactinomas in women. I: European Journal of Endocrinology. 2014 ; Vol. 170, Nr. 1. s. 31-38.

RIS

TY - JOUR

T1 - Giant prolactinomas in women

AU - Delgrange, Etienne

AU - Raverot, Gerald

AU - Bex, Marie

AU - Burman, Pia

AU - Decoudier, Benedicte

AU - Devuyst, France

AU - Feldt-Rasmussen, Ulla

AU - Andersen, Marianne

AU - Maiter, Dominique

PY - 2014

Y1 - 2014

N2 - Objective: To characterise distinctive clinical features of giant prolactinomas in women. Design: A multicentre, retrospective case series and literature review. Methods: We collected data from 15 female patients with a pituitary tumour larger than 4 cm and prolactin levels above 1000 mu g/l and identified 19 similar cases from the literature; a gender-based comparison of the frequency and age distribution was obtained from a literature review. Results: The initial PubMed search using the term 'giant prolactinomas' identified 125 patients (13 women) responding to the inclusion criteria. The female: male ratio was 1:9. Another six female patients were found by extending the literature search, while our own series added 15 patients. The median age at diagnosis was 44 years in women compared with 35 years in men (P<0.05). All cases diagnosed before the age of 15 years were boys. In women (n=34), we observed a minor peak incidence during the third decade of life and a major peak during the fifth decade. Amenorrhoea was a constant feature with seven cases of primary amenorrhoea. In eight women with onset of secondary amenorrhoea before the age of 40 years, the diagnosis was made 2-31 years later (median 9 years) and in all but one because of tumour pressure symptoms. The prolactin levels were above 10 000 mu g/l in 15/34 and misdiagnosis due to 'hook effect' occurred in two of them. Eighteen patients were treated with cabergoline; standard doses (<2.0 mg/week) were able to normalise prolactin in only 4/18 patients, and 7/18 patients were resistant to weekly doses ranging from 3.0 to 7.0 mg. Conclusion: Giant prolactinomas are rare in women, often resistant to dopamine agonists and seem to be distributed in two age groups, with a larger late-onset peak.

AB - Objective: To characterise distinctive clinical features of giant prolactinomas in women. Design: A multicentre, retrospective case series and literature review. Methods: We collected data from 15 female patients with a pituitary tumour larger than 4 cm and prolactin levels above 1000 mu g/l and identified 19 similar cases from the literature; a gender-based comparison of the frequency and age distribution was obtained from a literature review. Results: The initial PubMed search using the term 'giant prolactinomas' identified 125 patients (13 women) responding to the inclusion criteria. The female: male ratio was 1:9. Another six female patients were found by extending the literature search, while our own series added 15 patients. The median age at diagnosis was 44 years in women compared with 35 years in men (P<0.05). All cases diagnosed before the age of 15 years were boys. In women (n=34), we observed a minor peak incidence during the third decade of life and a major peak during the fifth decade. Amenorrhoea was a constant feature with seven cases of primary amenorrhoea. In eight women with onset of secondary amenorrhoea before the age of 40 years, the diagnosis was made 2-31 years later (median 9 years) and in all but one because of tumour pressure symptoms. The prolactin levels were above 10 000 mu g/l in 15/34 and misdiagnosis due to 'hook effect' occurred in two of them. Eighteen patients were treated with cabergoline; standard doses (<2.0 mg/week) were able to normalise prolactin in only 4/18 patients, and 7/18 patients were resistant to weekly doses ranging from 3.0 to 7.0 mg. Conclusion: Giant prolactinomas are rare in women, often resistant to dopamine agonists and seem to be distributed in two age groups, with a larger late-onset peak.

U2 - 10.1530/EJE-13-0503

DO - 10.1530/EJE-13-0503

M3 - Article

VL - 170

SP - 31

EP - 38

JO - European Journal of Endocrinology

T2 - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 1479-683X

IS - 1

ER -